IMMUNOTECH BIOPHARM LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.43 HKD | +0.88% |
|
+9.24% | -31.40% |
| Mar. 29 | Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023 | MT |
| Mar. 28 | Immunotech Biopharm Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
ETFs positioned on Immunotech Biopharm Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.77% | 4 M€ | -27.92% | ||
| 0.02% | 2 M€ | -.--% |
Immunotech Biopharm Ltd is a China-based investment holding company mainly engaged in the research and development, manufacturing and commercialization of immune cell products for treatments of cancers. Its main products are EAL, CAR-T cell series and TCR-T cell series products. EAL is a multi-target cellular immunotherapy product. It also provides cell cryopreservation services. The Company mainly conducts its businesses in the domestic market.
Calendar
2024-08-19
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -31.40% | 224M | |
| -1.65% | 103B | |
| +6.75% | 101B | |
| +5.71% | 23.07B | |
| -12.60% | 22.23B | |
| -9.70% | 18.05B | |
| -39.98% | 17.18B | |
| -10.17% | 16.94B | |
| +6.12% | 14.07B | |
| +35.47% | 12.35B |
- Stock Market
- Equities
- 6978 Stock
- Funds and ETFs Immunotech Biopharm Ltd
